Sponsors (5)
The bill strengthens consumer privacy and reduces the risk of foreign access to commercial genetic data at the expense of higher compliance costs, potential legal ambiguity for firms, and some loss of data access that could slow biomedical research.
Patients (including people with chronic conditions and disabilities) gain stronger privacy protections for sensitive genetic data because the FTC can treat commercial DNA firms' privacy violations as unfair or deceptive acts.
Individuals who used genealogy DNA services (as identified in the bill) are less likely to have their genetic data sold to or accessed by entities tied to the People's Republic of China, reducing the risk of foreign misuse of sensitive genetic information.
Commercial DNA testing companies face clearer legal limits on cross‑border transfers of genetic data, lowering some regulatory uncertainty about what data sharing is permitted.
DNA testing companies may incur higher compliance costs and potential revenue losses from restricted data‑sharing, costs that could be passed to consumers in the form of higher prices.
Hospitals, health systems, and researchers — and patients who benefit from biomedical research — may lose access to aggregated commercial genetic datasets, potentially slowing some biomedical studies and innovation.
The bill's prohibition uses broad language about entities 'under the influence, control, or ownership' of the PRC, which could create legal uncertainty for companies about when the restriction applies.
Based on analysis of 2 sections of legislative text.
Stops commercial ancestry/genealogy DNA services from selling or disclosing consumer genetic information to the People’s Republic of China or entities it controls and makes violations enforceable by the FTC.
Prohibits commercial DNA testing services that provide genealogical or ancestry information from selling or otherwise disclosing genetic information to the People’s Republic of China or to entities owned, controlled by, or under the influence of the People’s Republic of China. The bill treats such a sale or disclosure as an unfair or deceptive act and gives the Federal Trade Commission authority to enforce the ban using its full powers and remedies under the FTC Act. Defines key terms so the rule applies to genetic information originally collected from individuals by commercial ancestry/genealogy DNA services, and ties the definition of genetic tests to the existing federal genetic-information law (GINA).
Introduced March 24, 2025 by Timothy Burchett · Last progress March 24, 2025